Us8476268 alpelisib?

What is the purpose of the Us8476268 patent for alpelisib?

The Us8476268 patent, owned by Novartis, describes an improved phosphatidylinositol 3-kinase (PI3K) inhibitor, alpelisib, for cancer treatment [1]. The patent explains that alpelisib is effective against PI3K-alpha (PI3K-alpha) mutations, which are commonly found in various cancers.

How does alpelisib work compared to other cancer treatments?

Alpelisib targets PI3K enzymes, which are involved in cell signaling pathways, and inhibits their activity. This leads to reduced cancer cell proliferation and survival [2]. Compared to other cancer treatments, alpelisib has a more targeted approach, reducing the risk of damaging healthy cells.

When does the patent for alpelisib expire?

According to DrugPatentWatch.com, the Us8476268 patent is set to expire in 2030 [3]. However, as with many pharmaceutical patents, there may be ongoing litigation or disputes that could affect the patent's expiration date.

Who makes alpelisib, and what are its potential side effects?

Alpelisib is manufactured by Novartis, and its brand name is Piqray. The medication has been approved for patients with HR-positive, HER2-negative breast cancer [4]. Potential side effects of alpelisib include hyperglycemia, diarrhea, and increased cholesterol levels [5].

What are the implications for competitors and biosimilars?

As the patent for alpelisib is set to expire in 2030, other companies may begin to develop biosimilars or generic versions of the medication. This could lead to increased competition and potentially lower prices for the medication.

References:

[1] United States Patent and Trademark Office (2014). Us8476268: Novel phosphatidylinositol 3-kinase (PI3K) inhibitors and their use as anticancer agents. Retrieved from https://patents.google.com/patent/US8476268B2/en

[2] Novartis Pharmaceuticals (2020). PIQRAY (alpelisib) tablets. Retrieved from https://www.piqray.com/

[3] DrugPatentWatch.com (n.d.). Alpelisib - PIQRAY Patent. Retrieved from https://drugpatentwatch.com/patent/alpelisib-piqray

[4] Novartis Pharmaceuticals (2020). Piqray (alpelisib) tablets: Indications and usage. Retrieved from https://www.piqray.com/docs/piqray-prescribing-information.pdf

[5] FDA (2020). Piqray (alpelisib) tablets: Full prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf